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INTRODUCTION 
Research is showing that what was formerly referred to as 
"periodontal disease", is in fact multifactorial disease 
processes better referred to as "periodontal diseases". The 
microbiological spectrum with the immune system host 
resistance are paramount in importance in the recognition of 
etiology and diagnosis related to periodontal diseases. In 
addition, the criteria and methods for assessment of 
periodontal disease activity is receiving greater attention 
today than in the past. 
Recently, the American Academy of Periodontology 
recommended within the World Workshop in Periodontics, (July 
23-27, 1989), that periodontal disease be classified as shown 
in Table I. 
It was previously reported that periodontal disease was 
divided into periodontitis/periodontosis and gingivitis. 
Also, that gingivitis ultimately will lead to periodontitis. 1 
The current information available indicates that gingivitis 
does not necessarily result in periodontitis. 2 As is evidenced 
within this table, there are classified multiple terms of 
periodontal diseases, with associations to specific local 
bacterial etiology, and having a variety of immune/host 
1 
interactions which result in varying clinical 
manifestations. 2, 3 
Parameters used in the diagnosis of periodontal disease 
activity can be divided into two groups. First, clinical 
methods used to measure the defect, or lesion produced by the 
disease process in question; and secondly, laboratory 
measurement of etiologic agents or products site specificity 
related to microbial and subsequent disease process. 
The concept of an accurate diagnosis is further 
complicated due to periodontal disease going through periods 
of exacerbation and relative quiescence. 3•4•5•6 Once the 
periodontal disease process has been established, it is a 
common finding that a patient is referred to the periodontist. 
Yet, the state of the disease process: active {progressive) 
or inactive may be in question. There are currently three 
suggested models of periodontal disease activity. The three 
models include continuous paradigm, random burst theory, and 
asynchronous multiple burst hypothesis. 7 A common ingredient 
of all these models is inflammation which implicates the 
participation of one's immune system. Therefore, it is 
understandable that many clinicians find a sense of insecurity 
concerning the type of therapy to be utilized, the optimum 
time to initiate therapy and when to temporarily suspend 
therapy. 
It would be advantageous for a clinician if diagnosis and 
therapy could be correlated with respect to the individualized 
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patient's immune system, either locally or systemically. In 
this study, peripheral blood sera was examined from patients 
with periodontal disease for positive rheumatoid factor. 
Rheumatoid factors are basically autoantibodies. Rheumatoid 
factors have recently been detected in extracts from plaque, 
stimulated pooled saliva, and serum from patients having adult 
periodontitis. 8 Diagnosed rheumatoid arthritis cases were 
utilized as controls. 
HLA typing was performed for detection of Class II HLA-
DR4 in order to evaluate for occurrence with rheumatoid factor 
within periodontal patients and controls. Data was analyzed 
to determine whether patients with periodontal disease and 
positive rheumatoid factor share this specific HLA-DR4 
antigen. It is noteworthy that several chronic medical 
diseases with an autoimmune component and HLA association have 
been reported. They include IDDM Diabetes Mellitus, 
ankylosing spondylitis, 9•10 multiple sclerosis, 11 , 12 
ulcerative coli tis, 13, 14, 15 and juvenile rheumatoid 
arthritis. 16• 17 • 
Therefore, the purpose of this investigation was to 
analyze peripheral blood serum of patients with grouped 
classifications of periodontal disease for the occurrence of 
rheumatoid factor (RF) at varied titers utilizing the Rapi 
Tex* RF test and to perform human leukocytic antigen (HLA) 
typing for the association of the HLA-DR4 antigen. Patients 
diagnosed in medical health with generalized absence of 
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periodontal disease were utilized as controls. Additional 
controls consisted in diagnosed rheumatoid arthritis patients. 
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REVIEW OF THE LITERATURE 
Rheumatoid Factor 
The literature indicates that chronic inflammatory 
periodontal disease occurs through the interaction of 
plaque/bacteria and tissue lymphocytes of a susceptible 
host. 18• 19•20•2 Researchers Harkavy, J. et. al. , 21 Ellison, 
S.A. et al. , 22 Terner c. et al. , 23 and Rizzo et al. , 24 have 
implicated that one's immunological system and its mechanisms 
have a crucial role in periodontal disease. 
The human immunological system accounts for the ability 
to fight infection and disease. This system contains humeral 
and cell mediated responses. The immunoglobulins (Ig) are 
contained within the humeral system and consist of 5 classes, 
IgG, IgM, IgA, IgE, and IgD. The basic configuration of an Ig 
molecule is one which contains two heavy {H) chains and two 
light {L) chains held together with disulfide bridges. 
Furthermore, the H & L chain have variable regions and 
constant regions which possess different properties or 
functional capabilities. The Ig Molecule contains two Fab 
fragments and an Fe fragment. 25 , 26 
Antibodies are usually 
stimulation by foreign antigens. 
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produced in response to 
However, antibodies to ones 
own antigens called autoantibodies are being found with 
increasing frequency. Rheumatoid factors are antibodies which 
bind to the Fe portion of an Ig. They are usually of the IgM 
class and have a specificity for IgG immunoglobulins. 27, 28•29 
The name RF was given to this class of autoantibodies since 
they were first observed in patients suffering from RA. 30 RF 
is a major immunologic factor of RA, without implying that it 
is diagnostic. Contrary, studies show that only 50-70% of 
patients with RA demonstrate RF. 31 RF is also found in 2-10% 
of healthy patients. 32•33 Rheumatoid Factors are low 
affinity antibodies found in normal sera. 34 Higher levels 
of RF are reported with in patients with autoimmune disorders, 
chronic inflammation, 35 •36 and increase with age. 37 There 
are many other chronic diseases associated with Rheumatoid 
factor. A partial list of these diseases is included in Table 
II. 
The questions that have been asked repeatedly are: 1) 
What is the origin of RF, 2) What is the function of RF, and 
3) Do all human subjects have the capability to express RF? 
RF production can apparently be initiated by one of three 
pathways. The first pathway includes the production of RF by 
aggregated immune complexes38•39 or by the usual antigen 
antibody complex aggregates. 40•41 The second pathway by 
antigens having cross reactive 
The third possibility is 
activators. 44•45 •46 
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capabilities with IgG. 42 , 43 
by polyclonal B cell 
Data from Fong et al. , 47 and Carson et al. , 22 suggest 
that RF may serve functionally as physiological 
autoantibodies. Studies indicate that RF may be a form of 
enhancing phagocytosis of antigen/antibody complexes or 
aggregated antibodies. 48•49 Often times these RF persist in 
the sera which can possibly be explained by perturbations of 
the immune system in one of the following ways: persistent 
antigen stimulation, dysfunction with the immune regulation 
systems, or increased levels of immune complex formation. 
Fong et al. , 32 have concluded that: 1) the potential to express 
RF exists in nearly all humans, 2) the coding for RF is within 
the capability of genes of given germlines, and 3) the RF from 
a variety of autoimmune diseases or disorders have been 
derived from a common germline variable region (Vk) 
immunoglobulin. 
Balestrieri et al., 50 have demonstrated that purified RF 
inhibits the action of complement by two pathways: 
1). RF solubilizes immune complexes 
2). RF inhibits immune complex precipitation 
The inhibition in this case is dose-dependent. Furthermore, 
RF could not be found bound to complement. 
The results of Alvarella et al. , 51 suggest that two 
phenomena need to occur for the reduction of RF synthesis. 
These two phenomena are 1) the cross linkage of IgG, and 2) 
the influence of prostoglandin E2 (PGE2). PGE2 significantly 
inhibited RF and IgM secretion. Furthermore, PGE2 production 
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inhibited RF in the presence of T helper cells. 
The role and origin of RF is one that possesses many 
theoretical possibilities with regard to the function of our 
immunological system. Since RF is essentially an Ig, specific 
cell binding functions and properties exists. There is a vast 
amount of information that RF binds to mononuclear cells, 52 
neutrophil, 53 mast cells, 54 T Lymphocytes, 26 B lymphocytes, 55 
and complement. 56•57 Additionally, RF have the capability to 
express cross idiotypic reactivities which creates potential 
for a pathological process. 58 
Blackburn et al. 59 , found that RF stimulates neutrophil 
activity and the release of neutrophil enzymes. Aggregates of 
immune complexes can also cause release of these neutrophil 
enzymes. 
Burastero et al.~, have shown co5+ are antigens present 
on a subpopulation of B cells; CD5+ B cells are responsible 
for the production of autoantibodies. This study demonstrates 
that CD5+ B Cells (Approximately 20% of B cells population) 
are reactivated, expanded, and produce two subsets of RF: 1) 
polyreactive and low affinity and 2) monoreactive and high 
affinity for Fe fragment of IgG. 
Devy et al. 61 , suggest that the interaction between RF 
and immune complexes (Ic) may have a profound effect on 
processing, clearance, and tissue deposition of immune 
complexes. Although the process of immune complex clearance 
is beneficial, it is not clear how the presence of RF alters 
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the existing clearance system. 
PERIODONTAL DISEASE 
Doekes et al. 62 , suggest that RF may compete with the Fe 
portion of IgG and thereby effecting its ability to bind 
complement. The configuration, and binding sites have a role 
in complement binding activity. 
Periodontal disease being chronic in nature, involves the 
interaction of the aforementioned cell types. Additionally, 
vast amounts of literature have correlated. the presence of 
endotoxin with periodontal disease. 63, 64 , 65 
Aleo et al. , 45 found that endotoxin was present on 
diseased roots, and could not be found on uninvolved or 
unexposed root surfaces. 
The terms endotoxin, LPS and lipid A are often used 
synonymously in the literature, and contained within the cell 
wall of gram negative bacteria.~ Endotoxin has a significant 
role in virtually all forms of periodontal disease since gram 
negative microf lora is prevalent and associated with the 
etiology of the various forms of periodontitis. According to 
the Academy of Periodontology, the forms of periodontitis fall 
into one of the following classes: 1) Adult, 2) Juvenile, 3) 
Prepubertal, 4) Rapidly progressive, and 5) Refractory 
periodontitis. Each of the preceding classes have gram 
negative bacteria associated with their etiology. 
Additionally, Attstrom et al., 67 found presence of 
9 
complement, specifically C3 and C4 are found in both healthy 
and inf lamed tissues. However, levels of C3 and C4 were 
higher in the inflamed tissues. These results combined with 
the presence of endotoxin encourage the premise of localized 
responses to the inflammation of periodontal disease. 
Indeed, the complement system is activated, at least in part, 
at the gingival cervical site. Other studies showing cs 
present in inf lamed tissues include Brandtzaeg et al. , 68 
Platt et al. , 69 and Shilli toe et al. 70 Mast cells have been 
found to play a part in periodontal disease.. Additionally, 
periodontal disease is essentially a breakdown of connective 
tissues (CT) in the gingival tissues. Mast cells release many 
products which include: 1). histamine, 2) heparin, 3) tryptase 
and 4) chymase. Following the release of these products, are 
interactions with the connective tissues encouraging 
degeneration. Gruber et al. , 54 demonstrated that mast cell 
hyperplasia is a consistent finding of many diseases 
associated with CT alterations. The pathways which lead to 
mast cell activation include: 1) autoantibodies against IgE, 
2) IgE with specificity for gamma globulin complexes (either 
of these would aggregate IgE on the surface). 
Additionally, high affinity receptors for IgE are found 
on mast cells and leukocytes. Other inflammatory cells with 
FcR are monocytes, PMN's, platelets, eosinophils and 
Moqbel et al. , 71 demonstrated that the cross 
IgE results in the release of several 
basophils. 
linkage of 
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pharmacological mediators, which include histamine, 
1eukotrinenes, prostaglandins, and platelet activating factor. 
RHEUMATOID FACTOR AND PERIODONTAL DISEASE 
Gargiulo et al., 8 reported that peripheral blood serum 
from 25 of 30 patients diagnosed with advanced periodontal 
disease were positive for rheumatoid factor (RF} at serum 
titer of 1: 10. Rheumatoid factor production has been shown to 
be produced by genetically programmed CDS+ B cells. 72, 73 
Hirsch et al.,n performed a study involving 29 patients 
using the enzyme-linked immunospot (ELISPOT} to identify the 
number of IgA-RF and IgM-RF antibody secreting cells in the 
gingiva of adult periodontitis patients and also to determine 
the incidence of RF production with a simultaneous peripheral 
blood mononuclear cells (PBMC}. The conclusion of this study 
was 3 fold: 1) IgA-RF and IgG-RF secreting cells are 
frequently present; 2} RF in the gingiva is produced in the 
absence of peripheral RF, and, 3} that there is a lack of 
correlation between IgA-RF and IgM-RF suggesting that RF 
isotypes are regulated independently of each other. 
Meng HX et al.,~ evaluated T cell subsets in patients 
with marginal gingivitis, juvenile periodontitis, adult 
periodontitis, and health. The number of T cells was reported 
greatest in the disease tissues of adult periodontitis 
patients. Additionally, T cells were found in the least 
amount in the healthy group. It was interesting to note that 
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there was no significant difference in the ratios of T4/T8 
cells from diseased verses healthy tissues. 
MAJOR HISTOCOMPATIBILITY COMPLEX (HLA) 
In man the major histocompatibility complex is located on 
chromosome 6. These genes within the MHC code for polymorphic 
glycoprotein molecules called Human Leukocyte Antigens (HLA), 
consisting of Class I (HLA-A, -B, and -c locus) antigens; 
Class II (HLA-DP, -DQ, and -DR) Antigens and Class III 
( Complement C4 or C2 and properdin Factor. B) molecules. 25 
Antigens of the MHC were initially studied because of their 
importance in graft survival. Later gene products of the MHC 
were found to play a major role in antigen recognition by T 
cells76 as well as in the degree of immunologic 
responsiveness of T and B lymphocytes. 
Within the caucasian population, it has been reported 
that significant amount of HLA-DR4, -B27, and -A2, antigens 
are associated with rheumatoid arthritis, and ankylosing 
spondylitis. 77 HLA-DR4 belongs to the Class II type and 
therefore contributes to the activation of lymphocytes. 
As stated previously, HLA (Human Leukocyte Antigen) 
refers to polymorphic glycoprotein molecules within which the 
MHC antigenic specificities are encoded. Proteins encoded in 
the regime of the MHC are recognized to be involved in 
immunological recognition, interaction between lymphoid cells 
and antigen presenting cells. Class I antigens are located on 
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platelets and nucleated cells and Class II antigens are 
present on B lymphocytes, macrophages, monocytes, epithelial 
cells, melanoma cells, and activated T cells. The apparent 
function of Class II antigens is to present antigen to the T 
helper cells. 25 
The specific HLA - DR, - DP, and DQ antigens are of the 
Class II HLA molecule type. These antigens are found present 
on various cell subpopulations which are important in the 
presenting of foreign antigens to T helper cells. The 
documentation concerning the association of.HLA and several 
autoimmune disease is found at length. HLA antigen 
associations have been reported with Juvenile Rheumatoid 
Arthritis, 78 •79 ankylosing spondylitis, 80 diabetes 
melli tus, 81 •82 •83 multiple sclerosis, 84 • 85 ulcerative 
coli tis, 86•87•88 and a variety of other autoimmune diseases. 77 
HLA antigen DR4 has been shown to be associated with RA, 
and as described earlier, RFs are autoantibodies often found 
in RA. If RF is increased in periodontal disease, this 
association of HLA-DR4 and rheumatoid factor may be beneficial 
in identifying the risk of developing periodontal disease. 
MAJOR HISTOCOMPATIBLE COMPLEX AHD PERIODONTAL DISEASE 
Reinholdt et al. , 89 has found an increase in the 
frequency of HLA-A2, HLA-A28, and HLA BW15 in patients with 
juvenile periodontitis as compared with patients of the 
chronic periodontitis group which exhibited no significant 
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deviations from the general population. Furthermore, HLA-A2 
was reported found to be decreased in juvenile periodontitis 
(JP) and chronic periodontitis (CP) patients as compared to 
healthy subjects according to Kaslie et a1. 90 
svejgaard et al., 91 discussed three theories relating 
HLA to several diseases. Three of these theories have a 
particular interest in regard to HLA and juvenile 
periodontitis: 1) It is likely that the so called immune 
response (Ir) genes, which control our response to a variety 
of antigenic stimulus, are within the HLA complex. 2) For 
those cells which are immunocompetent, they serve as receptors 
for antigens and 3) Some microbial antigens may resemble HLA 
antigen and therefore, elicit no response, or a reduced 
response when they encounter the immune system of that 
particular HLA type. 
Katz et al., 92 recently found an insignificant 
difference in the frequencies of HLA -A, -Band -c antigens 
between patients and controls, but HLA- DR4 was shown to be 
highly associated with RA. Patients diagnosed as having 
rapidly progressive periodontitis are HLA -DR4 positive 80% of 
the time. However, the control groups are positive for HLA 
DR4 only 36% of the time. This report supports investigation 
demonstrating similarities between RF, HLA and periodontal 
disease. The only other study demonstrating an association- of 
HLA-D antigen and periodontal disease is the investigation by 
Saxen and Koskimies. 
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Wolf et al., 93 reported a 98% of patients of DR3 and DR4 
with diabetes· (insulin-dependent), with 51% being heterozygous 
DR3-DR4. Thus, the possibility of these antigens being 
involved partly in the production of immune responses heading 
to the pathogenesis of the pancreatic B cell destruction. It 
is possible that a virus or other environmental insult 
triggers an augmented or inappropriate immunological response 
in HLA-DR4 positive. 
A study by Cogen et al. , 94 was undertaken to identify 
possible etiology of localized juvenile periodontitis (LJP) or 
generalized juvenile periodontitis (GJP). Potential concerns 
were defects in leukocyte function or altered immunological 
responses under the control of MHC. Several significant 
findings were identified which include 1) decreased phagocytic 
and chemotactic function of the PMN's, 2) intrinsic cell 
defects in chemotaxis, 3) association between JP and HLA-DR2 
and HLA-A33 antigens (50% positive for HLA-DR2 and 36% 
positive for HLA-A33). The conclusion of this study is that 
defects in the PMN responsiveness, whether chemotactic or 
phagocytic, may allow an increased susceptibility of patients 
to aggressive and destructive form of periodontal disease such 
as JP. 
A potential mechanism for immune regulation is the 
differential expression of Class II antigens. Thus, a study 
by Walsh et al. , 95 was undertaken to see if a difference in 
expression of DR and DQ antigen of oral mucosal Langerhans 
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cells possibly exists between healthy and inflamed Langerhans 
cells. It was found that Langerhans cells in experimental 
gingivitis (8 days) express a larger number of DR than DQ 
antigens. 
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METHODS AND MATERIALS 
Forty patients selected from the patient population of 
Loyola University School of Dentistry volunteered for this 
research study. Each patient had the following information 
documented: age, race, medical history, social habits, dental 
history and examination. Patients presenting with a history 
of tumor, malignancy, blood transfusion, immunosuppressant 
therapy, psychiatric problems, or antibiotic therapy within 
the last three months did not participate. 
Patients were grouped as follows: 
Group I 
Group II 
Group III 
Medical health with generalized absence of 
periodontal disease. 
Medical health with moderate to advanced 
periodontal disease and associated bone loss. 
Diagnosed rheumatoid arthritis (RA), and 
having moderate to advanced periodontal 
disease with associated bone loss. 
The significance and procedure related to this investigation 
was explained to each participant. A participant was required 
to sign an "Informed and Consent Form" approved by the Human 
Research Review Committee of Loyola University Medical Center. 
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PERIODONTAL EXAMINATION 
The criteria for periodontal diagnosis consisted of a 
history, examination, and documentation. The periodontal 
documentation included pocket depth, full intra-oral 
radiographs, tissue changes (color), bleeding upon probing, 
level of oral hygiene at initial examination, and age at 
initial examination. The evidence of local etiology was 
recorded and evaluated as related to associated bone loss. 
The type of bone loss, vertical or horizontal, was indicated 
based upon radiographic and clinical examination. 
Patients were clinically diagnosed as follows: 
Type I Gingivitis-shallow pockets and no bone loss 
Type II Early periodontitis-moderate pockets, minor to 
moderate bone loss. Satisfactory topography and 
not tooth mobility. 
Type III Moderate periodontitis-moderate to deep pockets, 
moderate to severe bone loss, unsatisfactory 
topography and slight mobility of teeth. 
Type IV Advanced periodontitis-deep pockets, severe bone 
loss, advanced mobility patterns (usually missing 
teeth-may become prosthetic reconstruction cases) 
BLOOD DRAWING 
Peripheral blood draw was performed at the Pre-admission 
Testing Center at the Loyola McGraw Hospital. Each patient 
was scheduled by prior telephone notification to the HLA 
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center, (Clinical Immunology). The patient was discharged 
immediately after the drawing of blood and accompanied back to 
the Dental School. 
Peripheral venous blood was drawn from in accordance with 
accepted phlebotomy procedure. For this investigation 20 ml, 
of peripheral blood was drawn in heparinized tubes (green top) 
and 10 ml of peripheral blood was drawn in a serum tube (red 
top). 
Immediately after the blood draw, the green top tubes 
were forwarded to the Clinical Immunology Lab for HLA 
phenotyping and the red top tube sent to the Serology for 
Rheumatoid factor analysis. 
Rheumatoid factor titer were evaluated in a double-blind 
study at the following dilutions: >1:20, 1:20, 1:10, 1:5, and 
undiluted. The method utilized for evaluation was the Rapi 
Tex•1 RF Test which is a latex agglutination test for 
identification of rheumatoid factors. The RF evaluation was 
performed prior to periodontal treatment and a second test 
evaluation was performed utilizing -7o0c refrigerated serum 
and identical test kits. This later was done as an additional 
control. Testing procedures for RF were performed as 
previously stated within the Serology Laboratory of Loyola 
University Hospital by certified technicians. 
1
•Behring Diagnosis Inc., 17 Chubb Way, Somerville, NJ 
08876 
19 
The Rapi Tex* RF Test kit includes principles of the 
procedure, reagents, method, limitations of the procedure, 
expected values, and specific performance characteristics as 
described within the following paragraphs: 
PRINCIPLES OP TBB PROCEDURE 
The test is based on an immunologic reaction between 
rheumatoid factors as antibodies and the corresponding 
antigens. In this system, these antigens are heat-denatured 
human IgG coated on the surface of biologically inert latex 
particles. When mixed with a diluted serum sample containing 
rheumatoid factors, the particles agglutinate; in the absence 
of rheumatoid factors, no agglutination occurs. 
REAGENTS 
composition 
RF Latex Reagent - a suspension of polystyrene latex 
particles in glycine buffer, pH 8.2. The latex particles are 
coated with heat-inactivated human IgG. RF Latex Reagent is 
standardized with the World Health Organization RF standard. 
RF Positive Control Serum - a stabilized prediluted 
antihuman Ig serum (human) with an approximate IU/mL value on 
the label. 
Rapi Tex* Negative Control Serum a stabilized, 
prediluted human serum non-reactive with the latex reagent. 
All reagents contain 0.1% sodium azide as a preservative. 
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Method 
I. Qualitative Slide Test 
1. Bring all reagents and serum samples to room 
temperature. 
2. Prepare a 1:6 dilution of serum sample using normal 
saline, eg, 50 serum and 250 uL normal saline. The 
RF positive and negative controls _ are ready for 
use. The approximate screening sensitivity of the 
test with a 1:6 sample dilution is 20IU/mL. For 
screening at higher levels, a 1:20.sample dilution 
may be used. Increasing or decreasing sample 
dilutions will proportionally alter the sensitivity 
of the test system. 
3. Place 40 uL of controls and diluted sample on three 
separate fields the test slide. 
4. Gently mix the RF Latex Reagent to obtain a uniform 
suspension. Expel the contents of the dropper, 
ref ill and add 1 drop (-40 uL) to each field 
containing a sample to be tested. Mix well with a 
stirring respreading the mixture over most of the 
field. Tilt the slide through several planes for 2 
minutes. A rotary shaker may also used (145 to 160 
rpm). 
5. Examine for agglutination immediately using direct 
light ( eg, high intensity lamp) at a distance of 
approximately 10 to 15 cm from the surface of the 
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slide. Suitable equipment for analysis of 
agglutination tests may also be used. The reaction 
of the test serum is compared with the positive and 
negative controls. 
II. Quantitative Tube Dilution Test to report a tube titer 
value 
1. Label 12 test tubes and place in a rack. Pipet 1.9 
mL of normal saline into tube 1, 1.0 mL into tubes 
2 through 10 and 0.9 mL into tubes and 12. 
2 . Add 0. 1 mL of serum sample to tube 1. Mix and 
transfer 1.0 mL from tube 1 into tube 2. Continue 
this procedure through tube 10 and discard 1.0 mL 
from tube 10. 
3. Tubes 11 and 12 are controls. Pipet 0.1 mL of RF 
Positive Control to tube 11 and 0.1 mL of Rapi Tex* 
Negative Control into tube 12. 
4. Dilute the RF Latex Reagent 1:3 with normal saline 
and add 1 dropper to each tube ( 1 through 12) • 
Prepare diluted latex fresh daily. 
5. Shake the tubes and incubate for 15 minutes in a 
37°c water bath. 
6. Centrifuge the tubes at 400 to 900 RCF (relative 
centrifugal force) 1 to 2 minutes. 
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Relative Centrifugal Force (RCF) 
= 11.17 x r ( n )2 
1000 
r = radius of centrifuge in centimeters · 
n = revolutions/minute 
7. Gently shake the tube until the sediment is 
dislodged from the bottom. Then 'Carefully tilt the 
tube back and forth until an even suspension is 
obtained. 
8. Examine each tube for macroscopic agglutination 
with oblique illumination against a black 
background. 
Limitations of the Procedure 
For the qualitative slide test, reaction times longer 
than 2 minutes may produce false positive reactions. Markedly 
lipemic, contaminated, or plasma samples may also cause false 
positive reactions. Care should be taken to keep the RF Latex 
Reagent dropper vial tightly closed to prevent flocculation 
due to evaporation of the suspension. 
Strength of agglutination reaction is not indicative of 
the amount of RF activity present. 
Approximately 2% of sera obtained from healthy 
individuals give a positive RF reaction, with the incidence 
increasing with age. 96 Up to 6% of patients with other 
diseases (eg, hyper-y-globulinemia, liver diseases, chronic 
infections, collagen diseases other than rheumatoid arthritis) 
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may yield positive RF results.% Although the demonstration 
of RF is highly suggestive of rheumatoid arthritis it is not 
diagnostic for the condition, since it may occasionally be 
found in related (eg, lupus erythematosus) or unrelated 
disorders. 97•98•99 
Because of different test conditions, the Rapi Tex* RF 
quantitative tube dilution test is more sensitive than the 
Rapi Tex* RF qualitative slide test; therefore, the results 
obtained by these methods are not directly comparable. While 
the slide test provides a quick screening pro.cedure, the tube 
dilution test may be clinically more relevant by virtue of its 
ability to provide quantitative information. 
Expected Values 
The clinical significance of RF determination consists in 
differentiating between rheumatoid arthritis, in which 
rheumatoid factors have been demonstrated in the serum of 
approximately 80% of the cases examined, and rheumatic fever, 
in which the rheumatoid factors are usually absent. 97, 98, 99, 100 
It has been suggested that in quantitative latex tests, a 
positive agglutination at a dilution of 1:80 or greater is to 
be considered positive of RF. 100 If a sample has a titer of 20 
or 40 in the quantitative test, it is read as weakly reactive. 
The highest titers of RF activity are encountered in patients 
with active and chronic disease. 
24 
Specific Performance Characteristics 
Accuracy, Specificity and Sensitivity 
Serum samples from 71 apparently healthy blood donors 
tested with the Rapi Tex* RF quantitative tube dilution test 
yielded negative results in 99% of the cases. 
When 66 known RF-positive samples (from hospital 
populations) were assayed by the Rapi Tex* RF quantitative 
tube dilution test, all samples gave positive results, with 
titers ranging from 80 to 10240. 
Of 219 samples negative by the Waaler-Rose method, 99% 
were also negative by the Rapi Tex* RF qualitative slide 
procedure. 101 
Samples from 189 patients diagnosed as having rheumatoid 
arthritis, and yielding positive results by the waaler-Rose 
method, were assayed by the Rapi Tex* RF qualitative slide 
procedure. 
methods. 102 
Precision 
An agreement of 8 7 % was found between the two 
Six RF-positive sera covering a titer range from 160 to 
1280 were assayed by the Rapi Tex* RF quantitative tube 
dilution test over a 15-day period. Satisfactory performance 
was defined as ±1 tube dilution from the titer established on 
the first day of testing. An average reproducibility of 98% 
was achieved for the six samples. 
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TISSUE TYPING 
Human leukocytic antigen (HLA) typing was performed 
within the clinic immunological laboratory and the results was 
recorded for analysis. All patients that participated in this 
study were tested for the various HLA antigens (HLA-A, -B, -c, 
-DR, and -DQ antigens). Loyola University Medical Center, 
(Maywood, Illinois) currently uses the described method of HLA 
typing for HLA antigen determination in renal, cardiac, and 
bone marrow transplantation. This HLA typing technique has 
been documented in studies involving the association between 
HLA and autoimmune diseases. 
PRINCIPLES OF PROCEDURE: Lymphocyte separation, freezing and 
thawing. 
Lymphocytes were isolated from blood by a Ficoll-Hypaque 
density gradient. Washed lymphocytes, T cells and/or B cells 
were suspended in cold (0°C icebath) RPMI medium containing 
30% inactivated fetal calf serum and 10% DMSO, dispensed in 
Beckman vials (2 x 10 cells/vial), frozen overnight in a -76°C 
freezer and stored in liquid nitrogen. Shortly before use, 
lymphocytes were quickly thawed in a 37°c water bath, diluted 
with cold McCoy's medium containing Hepes buffer, centrifuged 
to remove DMSO and resuspended in the same medium to a 
concentration of approximately 2 x 10 lymphocytes per ml. 
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Tissue typing -- HLA Antigen Testing 
HLA-A,B,C typing is performed by the two stage 
microcytotoxici ty test. One hundred twenty sera were used to 
test for forty-one specific antigens. B lymphocytes for HLA-
DR and -DQ typing were isolated by the method of Danilovs et 
al. HLA-DR and -DQ typing is performed by the two stage 
microcytotoxicity test, modified to include longer incubation 
periods. Sixty sera were used to test for twelve HLA-DR and 
three HLA-DQ antigens. The sera used in typing were sera 
purchased on trays from One Lambda, Biotest and other 
companies. 
The principle of the microlymphocytotoxici ty test is that 
HLA-antisera will bind to respective cell membrane target HLA 
antigens on the surface of the lymphocytes. Complement is 
activated by the antigen-antibody complex on the cell 
resulting in cytolysis. The cytolysis is noted by the entry 
of nonfluorescent or florescent dyes into the dead cell which 
has undergone cytolysis. Recorded values of 8, (80-100% dead 
cells), indicate a strong positive reaction and presence of 
antigen; whereas a value of 1, {O -19% dead cells), indicates 
a negative interpretation and absence of antigen. Positive 
and negative controls are recorded for each test. HLA antigens 
are assigned after analysis of sera patterns, and cumulative 
data analyzed for association with the known periodontal 
clinical diagnosis. All HLA laboratory procedures were 
performed and documented by certified technicians utilizing 
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this procedure every day within the Loyola Immunogenics 
Laboratory. 
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RESULTS 
Forty patients participated in this research 
investigation. There were a total of fifteen male and twenty-
five females, whose ages ranged from 15 through 61 years. The 
mean age was 32.6 years. 
Patients were grouped according to ADA classification as 
Type I, Type II, Type III, or Type IV periodontitis. 
Detection of Rheumatoid Factor (RF) was performed at dilutions 
of >1:20, 1:20, 1:10,1:5, and undiluted utilizing the Rapi 
Tex* RF test. Two tests, (Test I and Test II), for 
peripheral blood RF were performed on each patient. RF was 
evaluated prior to periodontal therapy, and on patients 
without antibiotic treatment for the preceding three months. 
Test I was performed immediately after the initial blood draw. 
Remaining serum was frozen at -7o0c and utilized for Test II. 
Test II consisted in slowly thawing the serum and again 
performing the Rapi Tex* RF test. In Test II, all 40 patient's 
serum was simultaneously tested for RF. 
Table III describes the results of Test I (prior to 
periodontal therapy) and Table IV describes the results of 
Test II at the various dilutions for RF. Information 
regarding age, medical history, sex, ADA periodontal 
29 
classification, and the presence of HLA -DR4 and HLA -B27 are 
contained within Tables III through V. 
This study showed negative RF response to 1:20 and 1:10 
dilutions in Test I for all patients, regardless of medical 
histories, with the exceptions of two cases (Case #19 and Case 
#36). These two cases account for 5.4% of the control cases. 
Interesting to note, is that both of these cases were 
hypertensive patients. Additionally, two cases (Case #39 and 
#40), both of which were diagnosed rheumatoid arthritis 
patients, have positive tests at these dilutions. These two 
cases account for 66. 67% of the diagnosed rheumatoid arthritis 
patients. Although this higher percentage is one that is not 
surprising, it should be noted that the sample size of 
diagnosed rheumatoid arthritis patients was a limited to three 
cases. As further dilutions were tested, at 1:5 and 
undiluted, with the exception of case #31, only Case #19, 36, 
39, and 40 demonstrated positive response during Test I. Case 
#31 demonstrated a response using only the undiluted sample, 
which suggests low titers of RF and considered weakly 
reactive. These results were consistent during Test 2 with 
some variability of dilutions. Cases testing positive for RF 
were consistent during Test I and Test II. 
Table V summarizes the results of our HLA typing and was 
labeled as Test III. As can be calculated from the chart, are 
the percentage of patients with positive HLA-DR4, within the 
various ADA periodontal classifications, (I, II, III, and IV), 
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juvenile periodontitis (JP), and rapidly progressive 
periodontitis (RPP). Table VI reveals the percent HLA-DR4 as 
related to periodontal case type. Those cases having Type I 
classification demonstrates a 20% HLA-DR4 responses. The 
sample size of Type I cases were ten in number. Cases that 
were classified as having Type II periodontal disease 
demonstrated a significant response in 67% of cases tested. 
It should be brought to attention that this particular group 
had a small sample size of three patients which can be 
misleading in the interpretation as a significant response. 
Cases classified as Type III gave a 20% response to the 
presence of HLA-DR4. The sample size of Type IV patients was 
adequate with nine. Patients diagnosed as Type IV or juvenile 
periodontitis (JP) demonstrated a negative response to the 
presence of HLA-DR4. Again, the results for Type IV and JP may 
be misleading due to limited sample size of four cases with 
Type IV and two cases with JP. A 20% response was noted for 
rapidly progressive periodontitis cases having a sample size 
of nine. The total response of all cases regardless of 
periodontal classification, or medical history was 28% 
positive for HLA-DR4. 
Of the controls, regardless of periodontal case type, 23% 
were HLA-DR4 positive. Consistent with other studies, 103 
which indicate that many rheumatoid arthritis (RA) patients 
are positive for HLA-DR4, and that HLA-DR4 shows up in 
approximately 19% of all other cases which were negative for 
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Rheumatoid Arthritis. Those patients diagnosed with 
rheumatoid arthritis (RA), regardless of periodontal case 
type, were 66% HLA-DR4 positive, and is consistent with 
previous results. Al though 66% would be expected with 
diagnosed rheumatoid arthritis patients, the sample size in 
the present study was limited with three cases. Table VII 
summarizes the percent of HLA-DR4 positive controls versus 
rheumatoid arthritis patients. 
This investigation shows no correlation of peripheral 
blood samples with the presence of RF in patients with 
periodontal disease. Additionally, we found no correlation 
with the presence of HLA-DR4 combined with the presence of RF 
in patients with periodontal disease. With the exception of 
the diagnosed rheumatoid arthritis patients, none of the cases 
with a positive RF were HLA-DR4 positive. 
In comparing the positive rheumatoid factor reaction of 
Test I and Test II, it can be found that all positive 
reactions occurred in the same patients with one exception. 
Patient number 37 shows weakly positive in Test II at 1:20 and 
1:10 dilutions. Test I shows positive reactions for 5 
patients, (Case #19, 31, 36, 39, and 40) regardless of medical 
history, which was 15% of all cases tested. Test II shows 
positive reactions for 6 patients, (Case #19, 31, 36, 37, 39, 
and 40) regardless of medical history. It should be pointed 
out that 3 of these patients, in both test groups were 
diagnosed as having rheumatoid arthritis. Table VIII and 
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Table IX demonstrates the percent positive and negative 
response to rheumatoid factor test for Test I and Test II at 
the various dilutions. 
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DISCUSS I OB 
The origin of reported rheumatoid factor associated with 
periodontal disease is surrounded by the concept of local 
production or peripheral production of RF. The results from 
this study appear to favor the local production theory in that 
no correlation between peripheral blood samples with the 
presence of RF and periodontal disease was found. Hirsch et 
al.~ have reported data which supports the local production 
of RF. 
It is possible that peripheral production of RF reverts 
to a negative value upon disease elimination. Within this 
study peripheral blood samples were taken prior to disease 
elimination. 
Since periodontal disease is reported as cyclic in 
nature, it is possible that the patient population contained 
within this study had minimal stimulation of peripheral RF 
production because they were in a "nonprogressive" state. The 
diversity of the cases chosen and the clinical diagnosis of 
periodontal disease activity would tend to discount the 
latter. 
Williams and Kunkel et al. 104 have shown that patients 
with bacterial endocarditis and a positive peripheral RF will 
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revert to negative upon cure of the infection. This lends to 
an interesting thought that RF may very well be a diagnostic 
indicator as well as a prognostic indicator. 
Within the periodontium, the plasma cell is especially 
prominent in the established and advanced stages of 
periodontitis as shown by Page. 105 A recent article by 
Joachim, F., et al. 106 has shown a relationship between 
plasma cell counts and collagenolytic tissue destruction 
within Juvenile Periodontitis suggesting a possible 
correlation between anti-collagen antibody (RF) secretion. The 
authors concluded that the plasma cells constitute a large 
portion of the inflammatory cell count in advanced disease and 
are few in number within the clinically healthy periodontium. 
Of particular importance was the finding that increased 
numbers of plasma cells there was an observed increase in 
collagen destruction. This finding complicates the question 
as to the function of RF if a correlation between the number 
of plasma cells and positive RF is locally found within the 
periodontium. 
If periodontal disease is similar to other autoimmune 
type diseases, such as rheumatoid arthritis, we might expect 
and increase in RF production with disease progression or 
severity. Quite possibly the role for such an increase in RF 
may be protective in nature. 
performed. 
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Further studies need to be 
One of the ways white blood cells communicate with one 
another is through the interleukins. There is recent evidence 
showing the presence of local production of interleukins, 
Jandinski et al. 107 , McFarlane et al. 108 , Masada et al. 109 • 
Hall et al. 110 have demonstrated the localized 
production of Ig within the gingivae of JP patients. Manson 
et al. 111 and Spindler et al. 112 have reported that 72-73% 
of IgG within the gingivae is locally produced. Although 
recent investigations appear to favor local production, the 
author is of the opinion that peripheral production may play 
a role in the immune response, even if minimal, as a back up 
function if the primary source is compromised. The results in 
this study lend some support to this theory as the only 
positive RF groups were in the RPP or medically compromised 
patients. 
Additional controversy surrounds questions related to the 
function of RF. Answers are clearly mixed at this time, and 
require subsequent studies. Vaugh et al. 113 suggest that RF 
acts in a protective role by having the ability to combine 
with soluble antigen-antibody complexes making them less 
soluble. These less soluble complexes are cleared with greater 
ease by the reticuloendothelial system. Johnson & Faulk et 
al. 114 have shown that the presence of IgM-RF inhibits some 
in vitro complement dependent systems. Again, supportive of 
the protective function of one's immune system. 
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In a more recent paper, Bendtzen et al. 115 discuss the 
possibility of antibodies as being specific physiologic 
carriers and thus regulators of cytokines. The term cytokine 
is often used interchangeably with lympokine, however the term 
cytokine implies a wider range of non-antibody molecules, that 
may react with different cell types, including lymphocytes and 
monocytes. Lymphokines are soluble substances released by 
lymphocytes (T cells) forming a network of communication 
between cells of the immune system and their target organs. 
Examples of some lymphokines include macrophage activation 
factor (MAF), interforms (IFN) and osteoclast activating 
factor (OAF) • This carrier function may be beneficial in 
retarding the elimination from the circulation and at the same 
time protecting its proteolytic breakdown. 
It is quite possible that RF whether locally or 
peripherally produced in periodontal diseases may be aiding in 
the control rather than the pathogenesis of a chronic disease 
such as adult periodontitis. 
The results of this study show an absence of correlation 
between periodontal disease and positive peripheral blood RF. 
Gargiulo et al. 9 demonstrated RF positive agglutination within 
83.3% of the patients with peripheral blood serum at titer of 
1:10 and 6.6% at titer of 1:20 using a latex agglutination 
procedure. 
The latex agglutination procedure was first described by 
Singer et al. 116 The principle of this agglutination method 
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is based upon an antigen-antibody reaction. The rheumatoid 
factor is present in the sera will represent the antibodies 
and the antigens are the heat denatured human IgG coated on 
the latex particles, or appropriate carrier. The presence of 
RF can be considered positive upon recognized agglutination. 
Serial dilution of the sera provide an estimate as to the 
quantity of RF present. 
There were differences in the aforementioned study 
(Gargiulo et al.) compared to the present study in terms of 
the rheumatoid factor test which was employed. Doctor 
Gargiulo used the latex human IgG slide agglutination test -
Rheumanosticon2 for determination of rheumatoid factor. 
Additionally, the blood samples used by Dr. Gargiulo study was 
taken from the finger upon puncture. In many laboratories, 
the Rheumanosticon test has been substituted with the Rapi 
Tex*RF which was used in the present study. It is believed 
that the Rapi Tex* has a greater degree of accuracy with fewer 
false positive test as compared with similar RF test in the 
marketplace. Additionally the Rapi Tex*RF test is simple and 
easy to use. In the present study, the blood samples were 
taken by method of peripheral blood draw. The Rapi Tex* RF 
uses an IgG indication system which is similar to the 
Rheumanosticon RF test. 
2Rheumanosticon, Organon Diagnostics, A Division of 
Organon Inc., West Orange, New Jersey 07052 
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The Rapi Tex*RF test used in this study has an average 
reproducibility of approximately 98%, which is a high degree 
of reliability. False positive can be obtained if reaction 
time is longer than two minutes, samples are contaminated, and 
use of flocculated suspensions. Due to the limited number of 
positive RF responses and the consistency between Test I and 
Test II, it is unlikely that false positive test results 
played a significant role in our study. Approximately 2% of 
the healthy patients gave a positive RF reaction. Positive RF 
reactions are known to increase with age.~ 
Our immune system is in many ways controlled by the MHC. 
The MHC is the complex of genes responsible for the synthesis 
of cell surf ace antigens ref erred to as human leukocyte 
antigen (HLA) • Antigens, both self and non self, are 
apparently recognized by T cells only in conjunction with the 
MHC complex. HLA molecules generally fall into two 
categories: Class I, and Class II. Class I and Class II are 
separated from each other based upon function, distribution in 
tissue, and their structure. Taken from Schwartz et al. is 
Table V which compares Class I and Class II HLA antigens. 
Periodontal diseases share many of the characteristics of 
immune diseases reported associated with specific HLA 
antigens. These characteristics include: 1) unknown etiology, 
2) unknown progression or pathophysiology, 3) immunologic 
abnormalities ( such as neutrophil disfunction in JP patients) , 
4) hereditary pattern (however, studies show that there is no 
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absolute association with HLA antigen, but trends). 
The association of rheumatoid arthritis with HLA-DR4 is 
stated within the literature. 81 Based upon previous research 
related to RF, this study undertook to evaluate the occurrence 
of RF with HLA-DR4 within the patient with advanced 
periodontal disease. Of special interest was the RPP patient 
where a high incidence of occurrence was reported by Katz et 
al. 95 According to the previous investigator, HLA-DR4 was 
found in 80% of the patient population suffering with rapidly 
progressive periodontitis and 38. 3% of contro.ls. The results 
from the this study show the HLA-DR4 antigen to occur within 
33% of the patient population and 28% of the controls. The 
occurrence of the HLA-DR4 antigen did not correlate with the 
finding of positive RF with the exception of diagnosed RA. It 
is noted that the investigation reported by Katz, et al. had 
a more controlled population sample than the author's study. 
In classifying a patient as having rapidly progressive 
periodontitis, much is left to the diagnosing clinician. This 
discretion may lead to varying interpretation of research 
results. I suggest that before significant relationships 
between rapidly progressive periodontitis and HLA-DR4 pattern 
can be made, a consistent standard for diagnoses of rapidly 
progressive periodontitis be used especially since the 
etiology of RPP has a mixed interpretation. 
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CONCLUSION 
In conclusion, this study evidenced no correlation 
between the level of rheumatoid factor in peripheral blood 
with the severity of periodontal disease. Additionally there 
was no correlation between the severity of periodontal disease 
and the expressed HLA-DR4 Class II antigen •. 
Despite lack of a systemic correlation between Rheumatoid 
factor in peripheral blood and periodontal disease, the 
possibility may exist that rheumatoid factor is produced 
locally within the tissues of periodontium in advanced 
periodontal disease. Further investigation is needed to 
examine such expression. Also, as with the presence of 
rheumatoid factor in other chronic disease the possible role 
which rheumatoid factor may participate in the disease process 
remains to be clarified. 
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TABLE I 
Periodontal Disease Classification 
I. Gingivitis 
A. Acute 
B. Chronic 
II. Adult Periodontitis 
III. Early-Onset Periodontitis 
A. Prepubertal Periodontitis 
1. Generalized 
2. Localized 
B. Juvenile Periodontitis 
1. Generalized 
2. Localized 
c. Rapidly Progressive Periodontitis 
IV. Periodontitis Associated with Systemic Disease 
V. Necrotizing Ulcerative Periodontitis 
VI. Refractory Periodontitis 
Proceedings of the World Workshop in Clinical Periodontics 
42 
TABLE II 
CHRONIC ANTIGENIC STIMULATING DISEASES ASSOCIATED WITH 
RHEUMATOID FACTOR 
1. Acute pulmonary fibrosis 
2. Acute viral infections 
3. Aging (10 to 20% positive over age 65 
4. Ankylosing spondylitis 
5. Dermatomyositis 
6. Diabetes mellitus patients on insulin therapy 
7. Dysproteinemias and paraproteinemias 
8. Following multiple blood transfusions 
9. Following prophylactic vaccinations 
10. Idiopathic pulmonary fibrosis 
11. Liver disease (infectious hepatitis, biliary cirrhosis) 
12. Normal persons (2 to 4% of the population) 
13. Parasitic diseases 
14. Pneumonoconiosis 
15. Psychiatric disorders (schizophrenia, endogenous 
depression) 
16. Relatives of rheumatoid arthritis patients 
17. Rheumatoid arthritis 
18. Scleroderma 
19. Sjogren's Syndrome 
20. Subacute bacterial endocarditis 
21. Syphilis 
22. Systemic lupus erythematosus 
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Rheumatoid Factor (RF) 
TABLE III TEST I 
CASEI AGE MEDICAL SEX ADA 1:20 1:10 1:5 UD 
CASE1 2,4 NEG M I NEG NEG NEG NEG 
CASE2 25 NEG F I NEG NEG NEG NEG 
CASE3 27 NEG M I NEG NEG NEG NEG 
CASE4 25 NEG M I NEG NEG NEG NEG 
CASES 27 NEG M I NEG NEG NEG NEG 
CASES 2-4 NEG F I NEG NEG NEG NEG 
CASE7 25 MONO. F I NEG .NEG NEG NEG 
CASES 22 NEG F I NEG NEG. NEG NEG 
CASE9 15 NEG M I NEG NEG NEG NEG 
CASE10 23 NEG F I NEG NEG NEG NEG 
CASE 11 22 NEG F II NEG -NEG NEG NEG 
CASE12 26 THALASSEMIA F II NEG NEG NEG NEG 
CASE13 38 RF/MONO. F II NEG NEG NEG NEG 
HEPATTTIS 
CASE14 33 NEG M Ill NEG NEG NEG NEG 
CASE15 33 NEG M Ill NEG NEG NEG NEG 
CASE16 37 THROMBO- F Ill NEG NEG NEG NEG 
PLEBmS 
CASE17 5,4 NEG F Ill NEG NEG NEG NEG 
CASE18 45 CA OVARIES F Ill NEG NEG NEG NEG 
CASE19 38 HYPERTENSION F Ill NEG POS POS POS 
CASE20 61 OSTEO- M Ill NEG NEG NEG NEG 
ARTHRms 
CASE21 33 NEG F Ill NEG NEG NEG NEG 
CASE22 34 BENIGN TUMOR F Ill NEG NEG NEG NEG 
BREAST 
CASE23 38 NEG M IV NEG NEG NEG NEG 
CASE24 40 ULCER M IV NEG NEG NEG NEG 
CASE25 31 NEG F IV NEG NEG NEG NEG 
CASE26 56 NEG M IV NEG NEG NEG NEG 
CASE27 24 ASTHMA F JP · NEG NEG NEG NEG 
CASE28 20 NEG F JP NEG NEG NEG NEG 
CASE29 39 NEG M RPPnv NEG NEG NEG NEG 
CASE30 29 NEG F RPPnv NEG NEG NEG NEG 
CASE31 33 NEG F RPPnV NEG NEG NEG POS 
CASE32 22 NEG M RPPnV NEG NEG NEG NEG 
CASE33 31 CA CERVIX F RPPnv NEG NEG NEG NEG 
CASE34 30 NEG M RPPnv NEG NEG NEG NEG 
CASE35 34 NEG M RPPnv NEG NEG NEG NEG 
CASE36 36 HIP F RPPnv P0S POS POS POS 
CASE37 31 NEG F RPPnv NEG NEG NEG NEG 
CASE38 64 RA/SPINE F UI NEG NEG NEG NEG 
Ml 1884&86 
ASTHMA 
ART.la.ER. 
CASE39 46 IDOM/RA F • P0S POS POS WKPOS CASE40 43 RA F II NEG P0S POS WKPOS 
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Rheumatoid Factor (RF) 
TABLE IV TEST II 
CASEI AGE MEDICAL SEX ADA 1:20 1:10 1:5 UD 
CASE1 24 NEG M I NEG NEG NEG NEG 
CASE2 25 NEG F I NEG NEG NEG NEG 
CASES 27 NEG M I NEG NEG NEG NEG 
CASE4 25 NEG M I NEG NEG NEG NEG 
CASES Z1 NEG M I NEG NEG NEG NEG 
CASE6 24 NEG F I NEG NEG NEG NEG 
CASE7 25 MONO. F I NEG ·NEG NEG NEG 
CASES 22 NEG F I NEG NEG NEG NEG 
CASE9 15 NEG M I NEG NEG NEG NEG 
CASE10 23 NEG F I NEG NEG NEG NEG 
CASE 11 22 NEG F II NEG -NEG NEG NEG 
CASE12 26 THALASSEMIA F II NEG NEG NEG NEG 
CASE13 38 RF/MONO. F II NEG NEG NEG NEG 
HEPATITIS 
CASE14 33 NEG M Ill NEG NEG NEG NEG 
CASE15 33 NEG M Ill NEG NEG NEG NEG 
CASE16 37 THROMBO- F Ill NEG NEG NEG NEG 
PLEBms 
CASE17 54 NEG F Ill NEG NEG NEG NEG 
CASE18 45 CA OVARIES F Ill NEG NEG NEG NEG 
CASE19 38 HYPERTENSION F Ill POS POS NEG NEG 
CASE20 61 OSTEO- M Ill NEG NEG NEG NEG 
ARTHRms 
CASE21 33 NEG F Ill NEG NEG NEG NEG 
CASE22 34 BENIGN TUMOR F Ill NEG NEG NEG NEG 
BREAST 
CASE23 38 NEG M IV NEG NEG NEG NEG 
CASE24 40 ULCER M IV NEG NEG NEG NEG 
CASE25 31 NEG F IV NEG NEG NEG NEG 
CASE26 66 NEG M IV NEG NEG NEG NEG 
CASE27 24 ASTHMA F JP POS NEG NEG NEG 
CASE28 20 NEG F JP NEG NEG NEG NEG 
CASE29 39 NEG M RPPnv NEG NEG NEG NEG 
CASE30 29 NEG F RPPnv NEG NEG NEG NEG 
CASE31 33 NEG F RPPnv NEG NEG NEG POS 
CASE32 22 NEG M RPPnv NEG NEG NEG NEG 
CASE33 31 CA CERVIX F RPPnv NEG NEG NEG NEG 
CASE34 30 NEG M RPPnv NEG NEG NEG NEG 
CASE35 34 NEG M RPPnv NEG NEG NEG NEG 
CASE36 36 HIP F RPPnv P0S POS POS POS 
CASE37 31 NEG F RPPnV WKP WKP NEG NEG 
CASE38 54 RA/SPINE F HI NEG NEG NEG NEG 
. Ml 1984&86 
ASTHMA 
ART.SCLER. 
CASE39 48 IOOM/RA F u WKP P0S P0S NEG 
CASE40 '3 RA F II WKP P0S P0S NEG 
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HLA-antigen 
TABLE V TEST Ill 
CASEI AGE MEDICAL sex ADA DR4 B27 
CASE1 24 NEG M DR4 
CASE2 25 NEG F 
CASE3 27 NEG M 
CASE4 25 NEG M 
CASES 27 NEG M 
CASES 24 NEG F 
CASE7 25 MONO. F 
CASES 22 NEG F B27 
CASE9 15 NEG M 
CASE10 23 NEG F 
CASE 11 22 NEG F 
CASE12 26 THALASSEMIA F DR4 B27 
CASE13 38 RF/MONO. F DR4 
HEPATillS 
CASE14 33 NEG M Ill 
CASE15 33 NEG M Ill 
CASE16 37 THROMBO- F Ill B27 
PLEBms 
CASE17 54 NEG F Ill 
CASE18 -15 CA OVARIES F Ill 
CASE19 38 HYPERTENSION F Ill 
CASE20 61 OSTEO- M Ill OR4 
ARTHRmS 
CASE21 33 NEG F Ill OR4 
CASE22 34 BENIGN TUMOR F Ill 
BREAST 
CASE23 38 NEG M IV 
CASE24 40 ULCER M IV 
CASE25 31 NEG F IV 
CASE26 56 NEG M IV 
CASE27 24 ASTHMA F JP 
CASE28 20 NEG F JP 
CASE29 39 NEG M RPPnv B27 
CASE30 29 NEG F RPPnv DR4 
CASE31 33 NEG F RPPnv 
CASE32 22 NEG M RPPnv DR4 
CASE33 31 CA.CERVIX F RPPnv 
CASE34 30 NEG M RPPnv 
CASE35 34 NEG M RPPnv 
CASE36 36 HIP F RPPnv 
CASE37 31 NEG F APPnv 
CASE38 54 RA/SPINE F Ill 
Ml 1984&86 
ASTHMA 
ART.SCLER. 
CASES9 46 IOOM/RA F I DR4 
CASE40 a AA F UI DR4 
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TABLE VI 
Percent HLA-DR4 as related to periodontal case type 
Type I 
HLA-DR4 20% 
II 
67% 
III 
22% 
IV 
0% 
JP 
0% 
RPP 
22% 
Total 
28% 
Regardless of periodontal classification, HLA-DR4 was present 
in approximately 28% of all cases. 
47 
TABLE VII 
Percent of HLA-DR4 positive controls versus rheumatoid 
arthritis patients 
Total Patients 
Control 37 
RA 3 
Rheumatoid Arthritis (RA) 
HLA-DR4 positive 
9 
2 
48 
.% HLA-DR4 
23% 
66% 
TABLE VIII 
Test I: Percent positive and negative response to rheumatoid 
factor test 
Dilutions 
% positive reaction RF 
% negative reaction RF 
1:20 
5% 
95% 
49 
1:10 
10% 
90% 
1:5 
10% 
90% 
undiluted 
13% 
87% 
TABLE IX 
Test II: Percent positive and negative response to rheumatoid 
factor test 
Dilutions 1:20 
% positive reaction RF 12.5% 
% negative reaction RF 87.5% 
50 
1:10 
12.5% 
87.5% 
1:5 
7.5% 
92.5% 
undiluted 
2.5% 
97.5% 
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